CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 16, 2024 16:05 ET
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Pricing of Public Offering
December 12, 2024 20:19 ET
|
CG Oncology Inc.
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces Proposed Public Offering
December 11, 2024 06:17 ET
|
CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 06, 2024 08:00 ET
|
CG Oncology Inc.
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 05, 2024 07:00 ET
|
CG Oncology Inc.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 02, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 20, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 11, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024 08:23 ET
|
CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024 12:14 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab